Immix Biopharma, Inc.
IMMXNasdaq
$10.25
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↑ +247.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$567.5M
Enterprise Value
$477.0M
P/E
—
P/S
—
P/B
6.7
EV/EBITDA
—
PEG
—
FCF Yield
-5.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$34.9M
Free Cash Flow (TTM)
-$32.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-41.4%
ROIC
—
Debt / Equity
—
Net Cash
$90.6M
Return 1Y
+251.0%
Company profile
Immix Biopharma, Inc. engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination clinical trial in solid tumors of IMx-110 and anti-PD-1 Tislelizumab.
- CEO
- Ilya Rachman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- California
- Website
- immixbio.com
Management & directors
- Morris Gabriel SCFO
- Rachman Ilya MCEO and Chairman
Roles derived from SEC Form 4 filings.
Earnings
IMMX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.18↑ +20.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$453,852.00 | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M |
| Net income | -$1.1M | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| Diluted EPS | — | — | -$0.59 | -$0.89 | -$0.76 | -$0.89 |
| Operating cash flow | -$404,694.00 | -$1.6M | -$7.4M | -$11.4M | -$14.6M | -$23.9M |
| Free cash flow | — | -$1.6M | — | -$11.4M | -$15.8M | -$24.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.7M | -$7.4M | -$5.0M | -$4.7M | -$6.7M | -$7.7M | -$10.9M | -$10.8M |
| Net income | -$4.4M | -$7.1M | -$4.8M | -$4.5M | -$6.6M | -$7.6M | -$10.6M | -$10.1M |
| Diluted EPS | -$0.15 | -$0.24 | -$0.15 | -$0.15 | -$0.22 | -$0.24 | -$0.28 | -$0.18 |
| Operating cash flow | -$5.3M | -$4.0M | -$1.5M | -$1.7M | -$5.3M | -$5.9M | -$11.0M | -$9.8M |
| Free cash flow | -$5.4M | -$4.3M | -$2.0M | -$1.8M | -$5.4M | -$6.3M | -$11.2M | -$9.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-22 | Adams Helen C. | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-22 | Ng Carey | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-22 | Marquet Magda | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-22 | CHANG NANCY T | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-22 | Chudnovsky Yekaterina | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-22 | Hsu Jason | Award | 6,250 | $0.00 | $0.00 | filing |
| 2026-05-22 | BUCHAN MELISSA JANE | Award | 6,250 | $0.00 | $0.00 | filing |
| 2025-12-10 | Morris Gabriel S· CFO | Buy | 770 | $6.58 | $5,066.60 | filing |
| 2025-12-10 | Rachman Ilya M· CEO and Chairman | Buy | 746 | $6.67 | $4,975.82 | filing |
| 2025-12-08 | Morris Gabriel S· CFO | X | 156,000 | $0.80 | $124,800.00 | filing |
| 2025-09-17 | Rachman Ilya M· CEO and Chairman | Buy | 2,500 | $2.02 | $5,050.00 | filing |
| 2025-09-16 | Morris Gabriel S· CFO | Buy | 2,600 | $1.97 | $5,122.00 | filing |
| 2025-06-18 | Morris Gabriel S· CFO | Buy | 2,225 | $2.28 | $5,070.78 | filing |
| 2025-06-18 | Rachman Ilya M· CEO and Chairman | Buy | 2,178 | $2.30 | $4,998.51 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.